Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind tulisokibart trial in rheumatoid arthritis
jRCT2031250408Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of tulisokibart in rheumatoid arthritis (RA) (4 arms), sponsored by Merck & Co. Primary endpoint: ACR20 response at Week 12. Started Nov 2025; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2031250408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250408.